Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
Study sponsor: ImmunityBio, Inc. · IBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-12Actual
Enrollment · participants28Actual
Source updated2024-05-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.